PQ 145
145. Deputy Róisín Shortall asked the Minister for Health further to Parliamentary Question No. 535 of 20 September 2017, if his attention has been drawn to the impact that the changes of the prescribing of Lidocaine have had on persons with fibromyalgia; if the HSE medicines management programme has investigated the impact that changes to the prescription of pain medication has on persons with fibromyalgia; and if he will make a statement on the matter. [40839/17]
Introduced
27 September 2017
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
27 September 2017
Summary
145. Deputy Róisín Shortall asked the Minister for Health further to Parliamentary Question No. 535 of 20 September 2017, if his attention has been drawn to the impact that the changes of the prescribing of Lidocaine have had on persons with fibromyalgia; if the HSE medicines management programme has investigated the impact that changes to the prescription of pain medication has on persons with fibromyalgia; and if he will make a statement on the matter. [40839/17]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Medicinal Products Licensing
Medicinal Products Licensing
xml · EN · 27 September 2017
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2017-09-27/145/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2017-09-27/pq_145